U.S. Alvogen Eyes Stake In Bosnia’s Top Drug Firm; Plans to Create 200 New Jobs in Bosnalijek

August 25, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SARAJEVO, August 25 (Reuters) - U.S.-based generic drug maker Alvogen Inc is mulling the acquisition of a government stake in Bosnia's top drug firm Bosnalijek BSNL.SJ as a step to becoming a leading drug company in the region.

Twitter
LinkedIn
Facebook
Email
Print

Mergers & acquisitions Asia